Clinical Trials

Back to Search by Disease

11 results for Prostate Cancer

Phase I-II Study HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer With or Without Metastatic Disease

  • Condition: Prostatic Neoplasms
  • Intervention: Drug: HSV-tk +Valacyclovir in Combination with Brachytherapy
  • Study ID: NCT01913106
View Trial

MRI-Guided HDR Brachytherapy for Prostate Cancer

  • Condition: Patients With Prostate Cancer
  • Intervention: Procedure: MRI Guided Needles to deliver HDR Brachytherapy, Procedure: MRI Guided Needles to deliver HDR Brachytherapy
  • Study ID: NCT00913939
View Trial

Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

  • Condition: Prostate
  • Intervention: Drug: Olaparib
  • Study ID: NCT03047135
View Trial

Fluorine-18 - 2-(3-(1-carboxy-5-[(6-[18F]Fluoro-pyridine-3-carbonyl)-Amino]-Pentyl)-Ureido)-Pentanedioic Acid (18F-DCFPyL) Positron Emission Tomography / Computed Tomography (PET/CT) for Assessment of Recurrent Prostate Cancer

  • Condition: Prostatic Neoplasms, Prostate Cancer
  • Intervention: Drug: PSMA PET/CT scan
  • Study ID: NCT02899312
View Trial

Phase I Feasibility Trial of Stereotactic Re-irradiation of Prostate Cancer Recurrence Within the Definitively Irradiated Prostate

  • Condition: Locally Recurrent Prostate Cancer
  • Intervention: Radiation: Stereotactic Body Radiotherapy
  • Study ID: NCT03073278
View Trial

The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)

  • Condition: Prostate Cancer, Cardiovascular Disease
  • Intervention:
  • Study ID: NCT03127631
View Trial

A Feasibility and Safety Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Non-Resectable Pancreatic Cancer

  • Condition: Non-Resectable Pancreatic Cancer
  • Intervention: Biological: BPX-601, Drug: Rimiducid
  • Study ID: NCT02744287
View Trial

Open-label Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer

  • Condition: Recurrent Prostate Cancer
  • Intervention:
  • Study ID: NCT03067051
View Trial

PSMA-PET Registry for Recurrent Prostate Cancer Following Radical Prostatectomy

  • Condition: Recurrent Prostate Cancer
  • Intervention: Diagnostic Test: [18F]-DCFPyL PET/ CT scan (PSMA PET)
  • Study ID: NCT03718260
View Trial

68Ga-PSMA-11 PET in Patients With Prostate Cancer

  • Condition: Biochemically Recurrent Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
  • Study ID: NCT04777071
View Trial

A Phase 2 Study of Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Nivolumab
  • Study ID: NCT03637543
View Trial